Additional file 3: of The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer

Table S3A. Proteogenomics profiling of the expression of complement and complement- related components in patients with lung cancer. Table S3B. Median mRNA and protein levels in tissues and protein levels in serum. (XLSX 46 kb

Additional file 2: of The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer

Table S2. Datasets of expression levels of complement proteins extracted from published publications. (XLSX 84 kb

Additional file 4: of The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer

Supplementary Materials and Methods: Figure S1-S4. and Tables S4-S9. (DOCX 859 kb

Additional file 1: of The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer

Table S1. Datasets from microarray-based transcriptomic and RNA-Seq analyses extracted from published publications. (XLSX 166 kb

Additional file 1 of Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes

Additional file 1: Figure S1. Hematoxylin–eosin (HE) staining of all 15 NPC cell lines (× 20). Scale bars: 50 μm

Additional file 2 of Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China

Additional file 2. Fig. S1: Geographic distribution of anticancer bsAbs clinical trials. (A) Clinical trials of worldwide companies. (B) Clinical trials of China-initiated or involved R&D pharmaceutical companies

Additional file 3 of Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China

Additional file 3. Fig. S2: The MOA of bsAbs clinical trials. (A-B) The number of MOAs of international companies and China-initiated or involved companies, respectively. (C-D) Surface plot of MOA of international companies and China-initiated or involved companies, respectively

Additional file 1 of Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China

Additional file 1. Supplementary Methods and Table S1–6

Predictive value of immunotherapy-induced inflammation indexes: dynamic changes in patients with nasopharyngeal carcinoma receiving immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) have achieved substantial advancements in clinical care. However, there is no strong evidence for identified biomarkers of ICIs in NPC. In this retrospective study, 284 patients were enrolled into a training or validation cohort. Inflammatory indexes based on peripheral blood parameters were evaluated, including the systemic immune-inflammation index (SII), the neutrophil-lymphocyte ratio (NLR), the platelet-lymphocyte ratio (PLR), the lymphocyte-to-C-reactive protein ratio (LCR), and the lymphocyte-monocyte ratio (LMR). The optimum cut-off value for patient stratification was identified using X-tile. The Kaplan-Meier method and Cox’s proportional regression analyses were used to identify prognostic factors. Immunotherapy significantly changed the levels of SII, NLR, PLR, LCR and LMR in NPC patients. Patients with lower SII, NLR, and PLR, as well as those with higher LCR and LMR, before immunotherapy had superior PFS (all p p  Immune checkpoint inhibitor treatments significantly changed the levels of SII, NLR, PLR, LCR and LMR in NPC patients treated with immunotherapy. A lower baseline SII and a higher baseline LMR, and a reduction in SII and an elevation in LMR after immunotherapy are favorable factors for predicting survival among advanced NPC patients. There is no strong evidence for identified biomarkers of immune checkpoint inhibitors (ICIs) in nasopharyngeal carcinoma (NPC). Lower baseline SII and higher baseline LMR were related to better PFS. The dynamic changes of SII and LMR were independent prognostic factors for the survival of NPC patients receiving ICIs. Neutrophils, platelets, lymphocytes, and monocytes can be used as cheap and valuable biomarkers for predicting tumor response in NPC on immunotherapy.</p

Supplemental_Data_2_Supplemental_Table_and_Figure_changes_marked_yellow – Supplemental material for Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis

Supplemental material, Supplemental_Data_2_Supplemental_Table_and_Figure_changes_marked_yellow for Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis by Zhonghan Zhang, Kangmei Zeng, Shen Zhao, Yuanyuan Zhao, Xue Hou, Fan Luo, Feiteng Lu, Yaxiong Zhang, Ting Zhou, Yuxiang Ma, Yunpeng Yang, Wenfeng Fang, Yan Huang, Li Zhang and Hongyun Zhao in Therapeutic Advances in Medical Oncology</p